SUMA Technology and Newborn Screening Tests for Inherited Metabolic Diseases in Cuba
The ultramicroanalytic system (SUMA), created in the 1980s, is a complete system of reagents and instrumentation to perform ultramicroassays combining the sensitivity of the micro-enzyme-linked immunosorbent assay (ELISA) tests with the use of ultramicrovolumes. This technology permitted establishin...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SciELO
2016-07-01
|
| Series: | Journal of Inborn Errors of Metabolism and Screening |
| Online Access: | https://doi.org/10.1177/2326409816661356 |
| _version_ | 1818663571423232000 |
|---|---|
| author | Ernesto Carlos González Reyes PhD Elisa M. Castells MSc Amarilys Frómeta MSc Ana Luisa Arteaga MD Lesley Del Río MSc Yileidis Tejeda MSc Pedro L. Pérez LT Mary Triny Segura BSc Pedro Almenares MSc Yenitse Perea MSc Niurka M. Carlos MSc René Robaina MD, PhD José L. Fernández-Yero MD, PhD |
| author_facet | Ernesto Carlos González Reyes PhD Elisa M. Castells MSc Amarilys Frómeta MSc Ana Luisa Arteaga MD Lesley Del Río MSc Yileidis Tejeda MSc Pedro L. Pérez LT Mary Triny Segura BSc Pedro Almenares MSc Yenitse Perea MSc Niurka M. Carlos MSc René Robaina MD, PhD José L. Fernández-Yero MD, PhD |
| author_sort | Ernesto Carlos González Reyes PhD |
| collection | DOAJ |
| description | The ultramicroanalytic system (SUMA), created in the 1980s, is a complete system of reagents and instrumentation to perform ultramicroassays combining the sensitivity of the micro-enzyme-linked immunosorbent assay (ELISA) tests with the use of ultramicrovolumes. This technology permitted establishing large-scale newborn screening programs (NSPs) for metabolic and endocrine disorders in Cuba. This article summarizes the main results of the implementation during the 30 years of SUMA technology in NSP for 5 inherited metabolic diseases, using ultramicroassays developed at the Department of Newborn Screening at the Immunoassay Center. Since 1986, SUMA technology has been used in the Cuban NSP for congenital hypothyroidism, initially studying thyroid hormone in cord serum samples. In 2000, a decentralized program for the detection of hyperphenylalaninemias using heel dried blood samples was initiated. These successful experiences permitted including protocols for screening congenital adrenal hyperplasia, galactosemia, and biotinidase deficiency in 2005. A program for the newborn screening of CH using the thyroid-stimulating hormone Neonatal ultramicro-ELISA was fully implemented in 2010. Nowadays, the NSP is supported by a network of 175 SUMA laboratories. After 30 years, more than 3.8 million Cuban newborns have been screened, and 1002 affected children have been detected. Moreover, SUMA technology has been presented in Latin America for over 2 decades and has contributed to screen around 17 million newborns. These results prove that developing countries can develop appropriate diagnostic technologies for making health care accessible to all. |
| first_indexed | 2024-12-17T05:18:58Z |
| format | Article |
| id | doaj.art-5d98fe3871af403cbf5f26cf0c1ade7e |
| institution | Directory Open Access Journal |
| issn | 2326-4594 |
| language | English |
| last_indexed | 2024-12-17T05:18:58Z |
| publishDate | 2016-07-01 |
| publisher | SciELO |
| record_format | Article |
| series | Journal of Inborn Errors of Metabolism and Screening |
| spelling | doaj.art-5d98fe3871af403cbf5f26cf0c1ade7e2022-12-21T22:02:02ZengSciELOJournal of Inborn Errors of Metabolism and Screening2326-45942016-07-01410.1177/232640981666135610.1177_2326409816661356SUMA Technology and Newborn Screening Tests for Inherited Metabolic Diseases in CubaErnesto Carlos González Reyes PhD0Elisa M. Castells MSc1Amarilys Frómeta MSc2Ana Luisa Arteaga MD3Lesley Del Río MSc4Yileidis Tejeda MSc5Pedro L. Pérez LT6Mary Triny Segura BSc7Pedro Almenares MSc8Yenitse Perea MSc9Niurka M. Carlos MSc10René Robaina MD, PhD11José L. Fernández-Yero MD, PhD12 Department of Newborn Screening, Immunoassay Center, Cubanacan, Havana, Cuba Department of Newborn Screening, Immunoassay Center, Cubanacan, Havana, Cuba Department of Newborn Screening, Immunoassay Center, Cubanacan, Havana, Cuba National Programs Department, TecnoSuma Internacional SA Cubanacan, Havana, Cuba Department of Newborn Screening, Immunoassay Center, Cubanacan, Havana, Cuba Department of Newborn Screening, Immunoassay Center, Cubanacan, Havana, Cuba Department of Newborn Screening, Immunoassay Center, Cubanacan, Havana, Cuba Department of Newborn Screening, Immunoassay Center, Cubanacan, Havana, Cuba Department of Newborn Screening, Immunoassay Center, Cubanacan, Havana, Cuba Department of Newborn Screening, Immunoassay Center, Cubanacan, Havana, Cuba Immunoassay Center, Cubanacan, Havana, Cuba Department of Newborn Screening, Immunoassay Center, Cubanacan, Havana, Cuba Center of Molecular Immunology, Atabey, Havana, CubaThe ultramicroanalytic system (SUMA), created in the 1980s, is a complete system of reagents and instrumentation to perform ultramicroassays combining the sensitivity of the micro-enzyme-linked immunosorbent assay (ELISA) tests with the use of ultramicrovolumes. This technology permitted establishing large-scale newborn screening programs (NSPs) for metabolic and endocrine disorders in Cuba. This article summarizes the main results of the implementation during the 30 years of SUMA technology in NSP for 5 inherited metabolic diseases, using ultramicroassays developed at the Department of Newborn Screening at the Immunoassay Center. Since 1986, SUMA technology has been used in the Cuban NSP for congenital hypothyroidism, initially studying thyroid hormone in cord serum samples. In 2000, a decentralized program for the detection of hyperphenylalaninemias using heel dried blood samples was initiated. These successful experiences permitted including protocols for screening congenital adrenal hyperplasia, galactosemia, and biotinidase deficiency in 2005. A program for the newborn screening of CH using the thyroid-stimulating hormone Neonatal ultramicro-ELISA was fully implemented in 2010. Nowadays, the NSP is supported by a network of 175 SUMA laboratories. After 30 years, more than 3.8 million Cuban newborns have been screened, and 1002 affected children have been detected. Moreover, SUMA technology has been presented in Latin America for over 2 decades and has contributed to screen around 17 million newborns. These results prove that developing countries can develop appropriate diagnostic technologies for making health care accessible to all.https://doi.org/10.1177/2326409816661356 |
| spellingShingle | Ernesto Carlos González Reyes PhD Elisa M. Castells MSc Amarilys Frómeta MSc Ana Luisa Arteaga MD Lesley Del Río MSc Yileidis Tejeda MSc Pedro L. Pérez LT Mary Triny Segura BSc Pedro Almenares MSc Yenitse Perea MSc Niurka M. Carlos MSc René Robaina MD, PhD José L. Fernández-Yero MD, PhD SUMA Technology and Newborn Screening Tests for Inherited Metabolic Diseases in Cuba Journal of Inborn Errors of Metabolism and Screening |
| title | SUMA Technology and Newborn Screening Tests for Inherited Metabolic Diseases in Cuba |
| title_full | SUMA Technology and Newborn Screening Tests for Inherited Metabolic Diseases in Cuba |
| title_fullStr | SUMA Technology and Newborn Screening Tests for Inherited Metabolic Diseases in Cuba |
| title_full_unstemmed | SUMA Technology and Newborn Screening Tests for Inherited Metabolic Diseases in Cuba |
| title_short | SUMA Technology and Newborn Screening Tests for Inherited Metabolic Diseases in Cuba |
| title_sort | suma technology and newborn screening tests for inherited metabolic diseases in cuba |
| url | https://doi.org/10.1177/2326409816661356 |
| work_keys_str_mv | AT ernestocarlosgonzalezreyesphd sumatechnologyandnewbornscreeningtestsforinheritedmetabolicdiseasesincuba AT elisamcastellsmsc sumatechnologyandnewbornscreeningtestsforinheritedmetabolicdiseasesincuba AT amarilysfrometamsc sumatechnologyandnewbornscreeningtestsforinheritedmetabolicdiseasesincuba AT analuisaarteagamd sumatechnologyandnewbornscreeningtestsforinheritedmetabolicdiseasesincuba AT lesleydelriomsc sumatechnologyandnewbornscreeningtestsforinheritedmetabolicdiseasesincuba AT yileidistejedamsc sumatechnologyandnewbornscreeningtestsforinheritedmetabolicdiseasesincuba AT pedrolperezlt sumatechnologyandnewbornscreeningtestsforinheritedmetabolicdiseasesincuba AT marytrinysegurabsc sumatechnologyandnewbornscreeningtestsforinheritedmetabolicdiseasesincuba AT pedroalmenaresmsc sumatechnologyandnewbornscreeningtestsforinheritedmetabolicdiseasesincuba AT yenitsepereamsc sumatechnologyandnewbornscreeningtestsforinheritedmetabolicdiseasesincuba AT niurkamcarlosmsc sumatechnologyandnewbornscreeningtestsforinheritedmetabolicdiseasesincuba AT renerobainamdphd sumatechnologyandnewbornscreeningtestsforinheritedmetabolicdiseasesincuba AT joselfernandezyeromdphd sumatechnologyandnewbornscreeningtestsforinheritedmetabolicdiseasesincuba |